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ABSTRACT 
 
OBJECTIVE: The objective of this selective EBM review is to determine “Is famciclovir 
superior to valacyclovir as a treatment for recurrent genital herpes in reducing outbreak duration 
and frequency?” 
 
STUDY DESIGN: This review is based on three double-blind, randomized controlled trials 
(RCTs) published in 2006, 2008, and 2009. The studies compared the efficacy and safety of 
famciclovir (FCV) vs. valacyclovir (VCV) in the treatment of genital herpes. 
 
DATA SOURCES: All articles used were published in English, in peer-reviewed journals, and 
found using PubMed. 
 
OUTCOMES MEASURED: The effectiveness of famciclovir and valacyclovir was evaluated 
based on the proportion of patients with aborted lesions, the time to resolutions of lesions of 
active infection and all associated symptoms, the time to next reoccurrence, and the proportion of 
patients with a recurrence.  
 
RESULTS: All three studies found that there were no significant differences in efficacy or 
safety in terms of clinical disease manifestations between FCV and VCV. Median time to 
healing of herpes lesions was similar in both groups (4.25 days vs. 4.08 days), and about one-
third of patients in both groups experienced aborted lesions. A follow-up study showed similar 
times to next recurrence (33.5 days vs. 38 days). Values for evaluating frequency of recurrences 
proved to be similar as well, with 34% of the FCV group and 28% of the VCV group 
experiencing an outbreak within a 16-week post-treatment period, and the mean number of 
recurrences being 0.11 and 0.10, respectively.  
  
CONCLUSIONS: The results of the three RCTs demonstrate that famciclovir is equally 
effective compared to valacyclovir, but does not appear to be superior in treating genital herpes. 
However, the shorter dosing schedule of famciclovir for herpes recurrence may provide a more 
convenient treatment option for some patients, and further comparative studies are warranted to 
investigate whether improvements in virologic disease manifestations from previous in vivo 
murine studies translate into clinically meaningful results. 
 
KEY WORDS: Valacyclovir, famciclovir, recurrent, genital herpes. 
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INTRODUCTION 
Genital herpes is a highly contagious sexually transmitted disease most commonly caused 
by herpes simplex virus type 2 (HSV-2), although the rate of herpes simplex virus type 1 (HSV-
1) genital infection has been rising due to the increase in oral-genital transmission. After an 
initial HSV-2 infection, over 90% of patients experience a reactivation of latent virus residing in 
the cell bodies of neurons at some point in their lives, and about one-third have frequent 
outbreaks (>6 per year).1 Although non-lethal and often asymptomatic, recurrent outbreaks as 
well as the infections potential to the patient’s sexual partners results in significant psychological 
stress to the patient. Social stigma and shame also add to the negative impact on the patient’s 
quality of life. 3 While the disease remains incurable, treatment is possible. This paper evaluates 
three randomized trials (RCTs) comparing the efficacy and safety of famciclovir vs. valacyclovir 
in the episodic treatment of genital herpes. 
In the U.S., approximately 17% of adults are seropositive for HSV-2, making it one of the 
most common sexually transmitted diseases. Worldwide, the condition has become epidemic and 
the prevalence is 30%.1 The cost of incident infections was $1.8 billion in 2000, and projected to 
increase to $2.7 billion by 2025 as the incidence and prevalence continues to rise. Projected cost 
over the next 25 years is estimated at $61 billion. 5 Approximately 499,655 healthcare visits 
related to HSV occurred in 2000, with 2,056,1180 pharmacy claims. While these values clearly 
represent the severity of genital herpes as a public health problem, only 9%-50% of infected 
individuals are aware of their infection, which results in less healthcare visits than would be 
expected. 4 
It is unknown as to why some patients never have a subsequent outbreak while others 
have severe, continuous outbreaks. Still others may have asymptomatic recurrent reactivation of 
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virus. This variability in disease presentation further complicates its management and causes its 
transmission to be unpredictable.11 It is known that transmission can occur during active 
outbreaks and possibly during latent viral shedding, but there are no methods available to 
patients for them to definitively know when they are experiencing viral shedding, and no clear 
connection has been made between viral titer level and chance of transmission to a partner, with 
only the latter being clinically relevant. 9 Additionally, genital vs. oral and other forms of herpes 
infections cannot be differentiated based on seropositivity alone, making detection and screening 
a challenge.1 Finally, medical practitioners should be aware of the psychosocial concerns 
associated with genital herpes. Decreased self-esteem, anger, depression, social isolation, and 
guilt often accompany a new diagnosis. Many patients experience significant distress due to their 
perceived lack of control of the disease, sexual and/or social rejection, and the lifelong course of 
infectivity. 10 
Currently, three oral antivirals are approved for the treatment of genital herpes: 
Acyclovir (ACV), valacyclovir (VCV), and famciclovir (FCV). ACV was the first to be 
approved in the early 1980s, but its low bioavailability of 10-20% presented a possibility for 
drug improvement.  FCV, a prodrug of penciclovir (which is structurally similar to ACV), and 
VCV, the l-valine ester and prodrug of ACV, were discovered later on to have improved 
systemic absorption and longer duration of action. 7  Other treatments include over-the-counter 
pain relievers, such as ibuprofen and acetaminophen, and a wide range of alternative therapies, 
including but not limited to Echinacea, propolis, Prunella vulgaris, Rozites caperata, warm water 
soaks, lysine, baking soda, cornstarch, tea bags, ice, and aloe vera. 11 
Only the antiviral medications have been proven to be clinically effective in treating 
genital herpes. Most other methods are home-remedies for symptomatic relief and there is 
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limited, if any, scientific literature. Treatment with antivirals centers around three approaches: 
First occurrence, recurrence, and suppression. Early treatment soon after the first outbreak has 
been shown in mice to significantly reduce the possibility of future outbreaks by reducing the 
viral load that remains in the neural ganglia. Recurrent outbreaks are best treated within the first 
24 hours of prodromal symptoms due to the rapid burst of viral replication during this time. 
Various regimens of episodic therapy differing in drug quantity, dosing frequency, and length of 
treatment are available, ranging from 1-5 days. 1 Suppressive therapy on a daily basis reduces the 
frequency of recurrence and viral shedding.6 While various trials have already demonstrated the 
safety and improved efficacy of these antivirals compared to placebo within the three treatment 
modalities, few direct comparison RCTs of the antivirals have been performed. 7 
OBJECTIVE 
The objective of this systematic review is to determine “Is famciclovir superior to 
valacyclovir as a treatment for recurrent genital herpes in reducing outbreak duration and 
frequency?” 
METHODS 
 Specific selection criteria of three RCTs were used for this selective EBM review. The 
population chosen consisted of patients, at least 18 years of age, immunocompetent, with a 
history of frequent recurrent genital herpes (>4-6 recurrences per year). The intervention used in 
each RCT was FCV as daily and episodic therapy compared to VCV. All of the studies utilized 
included several outcomes but for the purpose of this review, the outcomes measured reflected 
the efficacy of FCV and VCV in reducing recurrent outbreak duration, frequency, and severity. 
Outcomes involving the virologic effects of the drugs were omitted from this review in order to 
focus on patient oriented evidence that matters (POEMs). 
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Some keywords utilized in the search for RCTs included valacyclovir, famciclovir, 
recurrent, and genital herpes. All articles were published in peer-reviewed journals and in the 
English language. The author researched the studies through PubMed and selected the articles 
based on their relevance to the clinical question and if they included POEMS. Inclusion criteria 
included RCTs published after 1996, with patients who had a clinical diagnosis with lab 
evidence of HSV, and at least 4 recurrences in the preceding 12 months prior to therapy. 
Exclusion criteria included patients under the age of 18, immunocompromised, renal disease, 
hepatic impairment, GI malabsorption, and pregnancy. The statistics reported or used in these 
studies were RRR, ARR, NNT, RRI, ARI, NNH, p-values, hazard ratios, and CIs. Table 1 shows 
the demographics and characteristics of the included studies. 
OUTCOMES MEASURED 
The outcomes measured were the proportion of patients with aborted lesions, the time to 
resolutions of lesions of active infection and all associated symptoms, the time to next 
reoccurrence, and the proportion of patients with a recurrence. These outcomes were measured 
by using patient self-reports and regular evaluations by clinical assessors throughout the study 
period to confirm or deny the presence of outbreak sign/symptoms and monitor lesion healing. 
1,2,6 Self-reports consisted of diary entries detailing the exact time of onset, symptoms, and the 
lesion stage. Full healing was defined as loss of crust with re-epithelialization of the skin. Those 
collecting the patient self-reports and the assessors themselves were blinded to the patients’ 
group assignment. 
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Table 1: Demographics & Characteristics of included studies 
 
Study Type # Pts. Age 
(yrs) 
Inclusion 
Criteria 
Exclusion 
Criteria 
W/D Interventions 
Abudalu1 
(2008) 
Double 
blind 
RCT 
1179 18-85 
years 
Patients 18 
years or older 
with a clinical 
diagnosis of 
HSV 1 or 2, 
lab evidence of 
HSV, hx of at 
least 4 
recurrences of 
genital lesions 
in the 
preceding 12 
mo. or prior to 
suppressive 
therapy 
Hx of renal dz, 
hepatic 
impairment, GI 
malabsorption, 
immunosuppre
-ssion, 
pregnancy, use 
of concomitant 
cimetidine 
and/or 
probenecid 
therapy 
57 1 tab 1 g 
famciclovir 
BID x 1 day 
vs. 1 tab 500 
mg 
valacyclovir 
po BID 3 
day. Therapy 
initiated 
w/in 6 hrs 
after the 
onset of 
prodromal 
symptoms 
and/or 
genital 
herpes  
Bodsworth
2 (2009) 
Double 
blind 
RCT 
666 >18 
years 
old 
Patients who 
successfully 
completed the 
Abudalu study 
and 
experienced a 
reoccurrence 
of genital 
herpes during 
the acute phase 
of the study 
Same as 
Abudalu 
0 Same as 
Abudalu 
Wald6 
(2006) 
Double 
blind 
RCT 
320 >18 
years 
old 
Patients 18 
years or older 
with a hx of at 
least 6 
recurrences in 
the past year, 
or prior to 
suppressive 
therapy 
Kidney 
impairment, 
liver dz, HIV, 
pregnancy, 
receipt of other 
investigational 
drugs, hx of 
resistant HSV 
infection, 
sensitivity to 
nucleoside 
analogues 
32 1 tab 250 mg 
famciclovir 
po BID vs. 1 
tab 
valacyclovir 
500 mg po 
qd 
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RESULTS 
This selective EBM review was performed on three RCTs, all of which performed a 
head-to-head comparison of famciclovir vs. valacyclovir in an adult, immunocompetent 
population 
Time to healing and resolution of symptoms. In the 2008 study by Abudalu et al, single 
day FCV (1000 mg bid) was compared to 3-day VCV (500 mg bid) in the episodic treatment of 
genital herpes. Both treatment groups exhibited similar time to healing of non-aborted lesions, 
4.25 days for patients receiving FCV and 4.08 days for patients receiving VCV, with a median 
treatment difference of 0.16 days (p= 0.48; 95% CI= -0.15 to 0.60) and hazard ratio of 1.08 (95% 
CI; 0.88-1.32). Time to resolution of all symptoms associated with infection, which included 
pain, itching, burning, tingling, and tenderness, were similar as well, with a median of 72.9 hours 
for FCV, 72.0 hours for VCV (p=0.75), and hazard ratio of 1.03 (95% CI=0.86-1.24) (Table 2).1 
 
Proportion of aborted lesions. Similar proportions of patients with aborted lesions 
following initiation of treatment were found between the two groups (32.7% of the FCV group 
and 33.6% of the VCV group). 1 
Table 3 displays the treatment effects on the proportion of patients with aborted lesions. 
The ARR shows an small increase in non-aborted lesions of the FCV group compared to having  
Table 2: Famciclovir vs. valacyclovir on the time to healing of lesions and all related symptoms 
(Abudalu et al., 2008)1 
Efficacy 
Parameter 
No. of 
patients 
Median days 
to healing of 
lesions 
Median days 
of difference 
in time to 
healing 
between 
treatments 
No. of 
patients 
whose 
symptom(s) 
resolved 
Median hours 
to resolution. 
Famciclovir 249 4.25 0.16 236 72.9 
Valacyclovir 253 4.08 238 72.0 
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non-aborted lesions with FCV treatment compared to VCV. NNT is calculated to determine the 
number of patients that need to receive FCV to prevent a bad outcome (non-aborted lesions). 
With a positive NNT, this is interpreted as single-day FCV treatment of 112 patients results in 
one more person developing non-aborted lesions compared to the VCV control group.  
Time to next recurrence. Bodsworth et al. in 2009 was a follow-up study of Abudalu et 
al. to assess the long-term effect of episodic treatment on disease progression. 87.6% (324/370) 
of the FCV recipients and 89.8% (342/381) of the valacyclovir recipients agreed to participate in 
this subsequent study, and they were prohibited from initiating suppressive therapy within the 6-
months following the healing of lesions. Of these patients, 61.1% of the FCV group and 60.6% 
of the VCV group experienced another recurrent outbreak during the follow-up period, with a 
mean time to next recurrence from treatment initiation of 33.5 days for FCV and 38.0 days for 
VCV (Table 4). 2 
Table 4: Time to next recurrence within 6-month follow-up period (Bodsworth et al., 2009)2 
 No. of 
patients who 
continued to 
the follow-up 
period 
No. of patients 
with next 
recurrence 
during follow-
up period 
Median days 
to next 
recurrence 
from treatment 
initiation 
Median of 
differences 
(days) 
95% CI 
Famciclovir 324 226 33.5 -3.00 (-8.00, 
2.00) Valacyclovir  342 231 38.0 
 
Table 3: Famciclovir vs. valacyclovir on the proportion of patients experiencing non-aborted 
lesions (Abudalu et al., 2008)1 
Proportion of 
VCV patients 
with non-aborted 
lesions 
Proportion of 
FCV patients 
with non-aborted 
lesions 
Relative Risk 
Reduction (RRR) 
Absolute Risk 
Reduction 
(ARR) 
Number needed 
to treat (NNT) 
EER - CER 
CER 
EER - CER 1/ARR 
0.664 0.673 0.014 0.009 112 
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Proportion with a recurrence. Suppressive therapy was analyzed in the study by Wald et 
al. by comparing 250 mg bid FCV with 500 mg q am VCV for 16 weeks, with primary endpoint 
being the proportion of patients that experienced a clinically confirmed recurrence during that 
period. The end results were similar between the two groups, with approximately 34% of the 
famciclovir group and 28% of the valacyclovir group having a recurrence at some point (Relative 
risk/hazard ratio = 1.10; 95% CI = 0.94-1.28). 6 
Table 5: Famciclovir vs. valacyclovir on suppression of genital herpes recurrences during 16 
weeks of administration (Wald et al., 2006)6 
 Proportion with 
a clinically 
confirmed 
recurrence 
Relative 
Risk/Hazard 
Ratio for 
Famciclovir 
95% CI P Value 
Famciclovir 34% 1.10 (0.94-1.28) P = 0.22 
Valacyclovir 28% 
Treatment effects on patients with a recurrence 
Proportion of 
VCV patients 
having a 
recurrence 
Proportion of 
FCV patients 
having a 
recurrence 
Relative Risk 
Reduction 
(RRR) 
Absolute Risk 
Reduction (ARR) 
Number needed to 
treat (NNT) 
  EER - CER 
CER 
EER - CER 1/ARR 
0.28 0.34 0.21 0.06 17 
 
Table 5 summarizes the results and treatment effects of Wald et al. The ARR shows a 
small increase in rate of recurrence with the FCV group compared to the VCV group, and RRR 
represents the effectiveness of FCV and the relative probability of experiencing a recurrence 
with FCV treatment compared to VCV. NNT is calculated to determine the number of patients 
that need to receive FCV to prevent a recurrence, interpreted as daily FCV treatment of 17 
patients over 16 weeks results in one more person developing a recurrence compared to the VCV 
control group. 
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Exclusions and compliance. All studies utilized consisted of similar inclusion/exclusion 
criteria, with a few exceptions. Abudalu et al. prohibited the use of concurrent cimetidine and/or 
probenecid therapy due to drug interactions and the possibility of increasing FCV and VCV drug 
levels, and only Wald et al. specifically stated that those with a history of HSV resistant to 
acyclovir or penciclovir were to be excluded. Both studies also commented on a high rate of 
compliance with study medications. For Wald et al., median adherence was 100% and 98% for 
the VCV and FCV arm, respectively, while Abudalu et al. reported that 97% of the FCV patients 
received the proper 2 doses on day 1 and 92.2% of the VCV patients received all 6 doses over 3 
days. 1,6 
Safety and Tolerability. Adverse events in all trials were mostly mild to moderate in 
intensity, with headaches and nausea being the most common. Rates of AEs were similar 
between the two drugs (23.2% for FCV and 22.3% for VCV, NNH = 112, Abudalu et al.) and 
consistent with previously established safety profiles. In Abudalu et al., 2 patients in the FCV 
arm reported serious AEs of myocardial ischemia and suicide attempt, and 1 patient of the VCV 
arm reported polysubstance abuse. Hiatal hernia and chest pain were the only serious AEs 
reported by 2 subjects in the VCV treatment group of Wald et al., and both were deemed 
unrelated to the study medication. 1,6 
Table 6: Adverse Effects (Abudalu et al., 2008) 
Control Event 
Rate (CER) 
Experimental 
Event Rate 
(EER) 
Relative risk 
increase (RRI) 
Absolute risk 
increase (ARI) 
Number needed 
to harm (NNH) 
EER - CER 
CER 
EER - CER 1/ARR 
.223 .232 0.0404 0.009 112 
  
 Table 6 outlines the treatment effects on AEs. A small RRI, ARI, and large NNH relative 
to the study indicate that AEs for both drugs were comparable. 
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DISCUSSION 
 While the trials by Wald et al. showed no major difference in time to first clinically 
confirmed recurrence, it did find a significant difference in time to first virologically confirmed 
recurrence and percentage of days with viral shedding, with VCV performing better than FCV. 6 
However, a clinical connection failed to be made with this data and thus was not be included in 
this SR. This limitation exists across many studies due to the fact that viral load has been shown 
to exhibit a complex relationship with disease pathogenesis and transmission. With transmission 
being a big concern for many patients, this relationship needs to be further explored. 10 
Likelihood of transmission is not based on viral titer alone, still occurs despite daily suppressive 
therapy, and may be affected by other factors such as site/size of area of exposure, viral strain, 
inoculum size, physiochemical barriers, innate immunity, and genetics. 9 The three trials 
analyzed in this review all showed similar efficacy between VCV and FCV based on clinically 
measurable factors, but Wald et al. and others have shown advantages to certain antivirals based 
on viral factors. 6,7 With FCV exhibiting a longer intracellular half-life, whereas VCV 
irreversibly terminates viral DNA replication, these subtle differences should encourage 
continued exploration on possible clinical benefits.7 Additionally, the release of the results from 
Wald et al. were delayed for 7 years by the pharmaceutical companies, possibly in an attempt to 
suppress unfavorable data against FCV. 6,7 
 The other limitation that remains in this SR is that Bodsworth et al. failed to include a 
placebo arm. Thus, assessments of short-course therapy on natural history of HSV could not be 
made. 2 
Acyclovir as an intervention was not considered in this review for a number of reasons. 
First of all, numerous RCTs have performed pair-wise comparisons of ACV with FCV and VCV, 
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already establishing comparable efficacy of the latter two with the former. Second, ACV’s low 
bioavailability is seen as a disadvantage compared to the other antivirals, especially with VCV 
being converted to ACV once systemically absorbed with higher serum concentrations. Finally, 
fewer head-to-head comparisons of FCV with VCV have been published, which was the desired 
focus of this review. 7 
While both FCV and VCV have already been established as relatively safe drugs, it 
should be made aware that one known case of VCV-induced psychosis and mania was reported 
in 2009 in an adolescent female with no previous psych history. Previously, similar findings have 
only been limited to the elderly and immunocompromised with ACV and penciclovir. This 
represents an incredibly rare but serious adverse effect. 8 
CONCLUSION 
Based on this review, famciclovir is not superior to valacyclovir as a treatment for genital 
herpes in reducing outbreak frequency and duration. However, it appears to at least be equally 
effective, and the shorter single-day dosing schedule of FCV for herpes recurrence may provide 
a more convenient treatment option for some patients. Further comparative studies are warranted 
to investigate whether improvements in virologic disease manifestations from previous in vivo 
murine studies translate into clinically meaningful results. 7 In addition, variations in dosing 
regimens should be considered. These explorations could potentially have huge implications in 
regards to herpes patients’ improvements in quality of life.  
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